InvestorsHub Logo
Followers 3
Posts 99
Boards Moderated 0
Alias Born 07/18/2016

Re: ngc1624_2 post# 2475

Monday, 10/03/2016 11:12:57 AM

Monday, October 03, 2016 11:12:57 AM

Post# of 7747
The abstract to be presented next week at EMSO announces a 95% disease control rate when combining aldoxorubicin with other treatments of choice. The phase 3 study shows that as a monotherapy aldoxorubicin is just as good or better than any other monotherapy. Looks like approval is in the works.